Trial · NCT03425643
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event Free Survival (EFS) | NAC + Neoadjuvant/Adjuvant Pembrolizumab | 47.2 | 95% Confidence Interval 32.9 to NA | Months | |
| Event Free Survival (EFS) | NAC + Neoadjuvant/Adjuvant Placebo | 18.3 | 95% Confidence Interval 14.8 to 22.1 | Months | |
| Overall Survival (OS) | NAC + Neoadjuvant/Adjuvant Pembrolizumab | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) | NAC + Neoadjuvant/Adjuvant Placebo | 52.4 | 95% Confidence Interval 45.7 to NA | Months | |
| Major Pathological Response (mPR) Rate | NAC + Neoadjuvant/Adjuvant Pembrolizumab | 30.2 | 95% Confidence Interval 25.7 to 35.0 | Percentage of Participants | |
| Major Pathological Response (mPR) Rate | NAC + Neoadjuvant/Adjuvant Placebo | 11.0 | 95% Confidence Interval 8.1 to 14.5 | Percentage of Participants | |
| Pathological Complete Response (pCR) Rate | NAC + Neoadjuvant/Adjuvant Pembrolizumab | 18.1 | 95% Confidence Interval 14.5 to 22.3 | Percentage of Participants | |
| Pathological Complete Response (pCR) Rate | NAC + Neoadjuvant/Adjuvant Placebo | 4.0 | 95% Confidence Interval 2.3 to 6.4 | Percentage of Participants | |
| Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score | NAC + Neoadjuvant/Adjuvant Pembrolizumab | -9.31 | 95% Confidence Interval -11.67 to -6.94 | Sore on a scale | |
| Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score | NAC + Neoadjuvant/Adjuvant Placebo | -10.73 | 95% Confidence Interval -13.07 to -8.40 | Sore on a scale | |
| Change From Baseline in Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score | NAC + Neoadjuvant/Adjuvant Pembrolizumab | -1.52 | 95% Confidence Interval -3.67 to 0.63 | Sore on a scale | |
| Change From Baseline in Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score | NAC + Neoadjuvant/Adjuvant Placebo | -3.74 | 95% Confidence Interval -5.96 to -1.52 | Sore on a scale | |
| Number of Participants Who Experience Perioperative Complications | NAC + Neoadjuvant/Adjuvant Pembrolizumab | 233 | Participants | ||
| Number of Participants Who Experience Perioperative Complications | NAC + Neoadjuvant/Adjuvant Placebo | 229 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03425643/results